Home Tools
Log in
Cart

VEGFR3/FLT4 Protein, Human, Recombinant (His)

Catalog No. TMPY-00949
Synonyms: VEGFR-3, PCL, FLT41, VEGF Receptor 3, VEGFR3, FLT-4, fms related tyrosine kinase 4, LMPH1A, FLT-41

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
VEGFR3/FLT4 Protein, Human, Recombinant (His)
Pack Size Availability Price/USD Quantity
100 μg In stock $ 386.00
200 μg 5 days $ 682.00
500 μg 5 days $ 1,440.00
Bulk Inquiry
Get quote
Select Batch  
Contact us for more batch information
Biological Description
Technical Params
Product Properties
References and Literature
Biological Information 1. Measured by its binding ability in a functional ELISA. 2. Immobilized human VEGF-C at 10 μg/mL (100 μl/well) can bind human VEGFR3-his. The EC50 of human VEGFR3-his is 0.011 μg/mL.

Description Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
Species Human
Expression System HEK293
Tag His
Accession Number P35916-1
Synonyms VEGFR-3, PCL, FLT41, VEGF Receptor 3, VEGFR3, FLT-4, fms related tyrosine kinase 4, LMPH1A, FLT-41
Construction A DNA sequence encoding the extracellular domain (Met 1-Ile 776) of human VEGFR3 (NP_002011.2) was expressed with a C-terminal polyhistidine tag.
Protein Purity > 97 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.

Molecular Weight Approxiamtely 86 kDa
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Formulation Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
Reconstitution A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
Stability & Storage

Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Shipping

In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

Research Background Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

References and Literature

Calculator

Reconstitution Calculator
Recombinant Proteins Dilute Calculator
Specific Activity Calculator
=
÷
X
=
X
(Unit/mg)
= 106 ÷
ng/mL

bottom

Tech Support

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords

VEGFR3/FLT4 Protein, Human, Recombinant (His) VEGFR-3 FLT4 PCL FLT41 VEGF Receptor 3 VEGFR3 FLT 4 FLT-4 fms related tyrosine kinase 4 LMPH1A FLT 41 VEGFR 3 FLT-41 recombinant recombinant-proteins proteins protein

 

TargetMol